Literature DB >> 15527257

Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114).

Arun K Ghosh1, Sofiya Leshchenko, Marcus Noetzel.   

Abstract

A convenient synthesis of (3R,3aS,6aR)-3-hydroxyhexahydrofuro[2,3-b]furan, a high-affinity nonpeptidal ligand for HIV protease inhibitor UIC-94017, is described. This inhibitor is undergoing advanced clinical trials. The synthesis utilizes a novel stereoselective photochemical 1,3-dioxolane addition to 5(S)-benzyloxymethyl-2(5H)-furanone as the key step. The requisite furanone derivative was prepared in high enantiomeric excess by an immobilized lipase-catalyzed selective acylation of (+/-)-1-(benzyloxy)-3-buten-2-ol and a ring-closing olefin metathesis with Grubbs' catalyst. Optically active bis-THF was converted to protease inhibitor 2 (UIC-94017).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15527257     DOI: 10.1021/jo049156y

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  41 in total

1.  Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.

Authors:  Kazuhiko Ide; Manabu Aoki; Masayuki Amano; Yasuhiro Koh; Ravikiran S Yedidi; Debananda Das; Sofiya Leschenko; Bruno Chapsal; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.

Authors:  Yasuhiro Koh; Manabu Aoki; Matthew L Danish; Hiromi Aoki-Ogata; Masayuki Amano; Debananda Das; Robert W Shafer; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

3.  A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.

Authors:  Ravikiran S Yedidi; Harisha Garimella; Manabu Aoki; Hiromi Aoki-Ogata; Darshan V Desai; Simon B Chang; David A Davis; W Sean Fyvie; Joshua D Kaufman; David W Smith; Debananda Das; Paul T Wingfield; Kenji Maeda; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

4.  Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Ravikiran S Yedidi; Rui Zhao; Hironori Hayashi; Kazuya Hasegawa; Tomofumi Nakamura; Cuthbert D Martyr; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

5.  Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.

Authors:  Yasushi Tojo; Yasuhiro Koh; Masayuki Amano; Manabu Aoki; Debananda Das; Sarang Kulkarni; David D Anderson; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

6.  A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.

Authors:  Masayuki Amano; Yasuhiro Koh; Debananda Das; Jianfeng Li; Sofiya Leschenko; Yuan-Fang Wang; Peter I Boross; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

7.  Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants.

Authors:  Arun K Ghosh; Kalapala Venkateswara Rao; Prasanth R Nyalapatla; Satish Kovela; Margherita Brindisi; Heather L Osswald; Bhavanam Sekhara Reddy; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Shin-Ichiro Hattori; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2018-03-15       Impact factor: 3.466

8.  In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.

Authors:  Yasuhiro Koh; Masayuki Amano; Tomomi Towata; Matthew Danish; Sofiya Leshchenko-Yashchuk; Debananda Das; Maki Nakayama; Yasushi Tojo; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

9.  A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Rui Zhao; Ravikiran S Yedidi; Debananda Das; Haydar Bulut; Nicole S Delino; Venkata Reddy Sheri; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

10.  Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model.

Authors:  Debananda Das; Yasuhiro Koh; Yasushi Tojo; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Chem Inf Model       Date:  2009-12       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.